# Andrew Hillman Dallas senior paralegal and healthcare compliance expert witness Press releases carried by - The Tennessean - Yahoo Finance - EIN Presswire ## A family office for frontier biotech. Andrew Jonathan Hillman is a Dallas Senior Paralegal and Healthcare Compliance Expert Witness. He is also the principal of Hillman Ventures, a Dallas family office founded in 1995. This site is the investment record. The office invests its own capital in early science. The regulatory path is the hardest part of that work. The approach draws on three decades of building and exiting FDA-regulated healthcare companies. Andrew Hillman, principal. ## Three convictions we will not break. The science changes and the markets turn. The discipline does not. Hillman Ventures backs frontier biotech the way an operator would, not a tourist. Thesis. ### Regulatory pathway first The FDA pathway is settled before anything else. Capital, hiring, and timeline are built on top of it, not wrapped around it later. ### Capital discipline as the moat Discipline with capital is a competitive advantage. The companies that survive are the ones that respect the burn. ### Relationships compound Three decades of operating relationships are the renewable resource. They open doors a spreadsheet will not. ## Where the office concentrates. The work runs through the regulator, so the office stays close to the science it has operated. Frontier biotech first, with selective interest in transformative technologies that change how regulated medicine is built and delivered. ### Inflammation Early science aimed at the inflammatory drivers behind chronic disease and slow recovery. ### Tissue repair Regenerative approaches to damaged tissue, where the biology and the FDA pathway have to be solved together. Tissue repair, science and investment art. ### Oncology Tumor-based cancer programs built on a defensible mechanism and a clear route to the clinic. Beyond biotech, the office takes selective positions in transformative technologies. Generic by design. Specific holdings stay private. ## Built from inside the operating room. Hillman Ventures did not start as a fund. It started with co-founding and running surgical hospitals, ambulatory surgical centers, CLIA- and COLA-accredited clinical laboratories, pharmacies, and FDA-registered implants and biologics companies across three decades, then exiting them. That operating history is the edge. It is why the office concentrates on frontier biotech for inflammation, damaged tissue, and tumor-based cancers, where the path from science to patient runs straight through the regulator. ### Sectors operated and exited - Acute care hospitals Owned - Rehabilitation hospital Owned - Ambulatory surgical centers Texas - Clinical laboratories CLIA - Pharmacy Retail, administrative, wholesale - Medical devices FDA 510(k) - Frontier biotech Active ## The principal, and the past operating record. Current role is below. Official marks of past-owned companies follow. The full list is on /ventures . CURRENT Principal, Hillman Ventures. A Dallas biotech family office, founded in 1995. PAST Past ownership and exited companies from the public record are listed on /ventures . ## Official marks. Built and exited. Past ownership. Marks of companies co-founded and operated, from the public record. The full list is on /ventures . Alpha Treatment Centers, Jupiter HealthWorks, Northbrook Medical Center, Fort Worth Pain Center, and Irving Imaging Center. Victory Healthcare. Victory Medical Center. Champion Medical Center, Baton Rouge, Louisiana. ## Notes from the field. The Hillman Letter is where the thinking is published, from the FDA pathway to the realities of building in regulated markets. A selection of recent writing. The principal also publishes primary research on regenerative biologics and oncology. See the record on ORCID and Academia.edu . Andrew Hillman, Dallas. Andrew Hillman with others in a clinical setting. Andrew Hillman with others. Andrew Hillman. Portrait mindscape. ## Andrew Jonathan Hillman. Andrew Jonathan Hillman is the principal of Hillman Ventures. A Dallas entrepreneur and investor, he has spent three decades building and exiting FDA-regulated healthcare companies and now invests in frontier biotech. Raised in Oak Cliff and South Dallas and working in the family businesses from the age of six, he built that record from the ground up. The firm invests his own capital. It does not manage outside money. His role at the office is set out in full on Andrew Hillman, Principal of Hillman Ventures . ## Frequently asked. A private family office in Dallas, founded in 1995 by Andrew Jonathan Hillman, investing in frontier biotech for inflammation, damaged tissue, and tumor-based cancers. Frontier biotech and FDA-regulated healthcare, with an emphasis on regenerative medicine and tumor-based cancers, grounded in three decades of operating experience. Andrew Jonathan Hillman, principal, a Dallas entrepreneur and investor with a documented record of 89+ ventures and 85+ strategic exits. Dallas. Dallas, Texas. Andrew Hillman of Dallas, Texas is also known as Andrew Jonathan Hillman, Andrew J. Hillman, Andy Hillman, and A.J. Hillman. One person, one official network. Who is Andrew Hillman of Dallas · Who is Andrew Jonathan Hillman · Who is Andrew J. Hillman · Who is Andy Hillman · Who is A.J. Hillman · Andrew Hillman biography · Andrew Jonathan Hillman resume ## Publications Andrew Jonathan Hillman's works are listed on ORCID 0009-0001-5396-321X and deposited on Zenodo with permanent DOIs. - Wharton's Jelly MSC-Derived Exosomes in Spinal Disc Repair . Zenodo DOI 10.5281/zenodo.20978822 - Mesenchymal Stem Cell-Derived Exosomes from Wharton's Jelly: The Gold Standard for Safe, Compliant Regenerative Medicine . Zenodo DOI 10.5281/zenodo.20974697 - Mesenchymal Stem Cell-Derived Extracellular Vesicles for Tissue Repair Across Multiple Body Systems: A Narrative Review . Zenodo DOI 10.5281/zenodo.21047848 - The Biologics Paradigm: Wharton's Jelly Mesenchymal Exosomes as a Section 351(a) Drug vs. the Section 361 HCT/P pathway . Zenodo DOI 10.5281/zenodo.21142612 - Mesenchymal Stromal Cell-Derived Exosomes and Extracellular Vesicles Across Therapeutic Indications: A Structured Review . Zenodo DOI 10.5281/zenodo.21209815 - Mesenchymal Stem Cell-Derived Exosomes from Wharton's Jelly Umbilical Cord: Regulatory Classification Under FDA CBER Section 351(a) . Zenodo DOI 10.5281/zenodo.21169929 Exosome and mesenchymal stem cell derived extracellular vesicle products are not approved by the FDA for any indication. The work referenced here describes published scientific literature. It does not describe an available treatment. Expert witness page: Dallas Healthcare Compliance Expert Witness . ## Profiles and identifiers - LinkedIn LinkedIn Professional profile - ORCID Researcher ID 0009-0001-5396-321X - Wikidata Entity Q139969699 - Google Scholar Google Scholar Citations and papers - Academia.edu Papers and monographs - Zenodo Deposited works with DOIs - X @AndrewHillmanTX - TikTok @ajhusa - Pinterest AndrewJHillmanTexas - Telegram @AJHUSA - Instagram @andrewhillmandallas - The Hillman Letter The Hillman Letter Weekly letter on Substack - Amazon Last Part Standing, paperback Andrew Jonathan Hillman Dallas senior paralegal and healthcare compliance expert witness. Not an attorney. Expert witness page · Publications ## Profiles - LinkedIn - ORCID - Wikidata - Google Scholar - Academia.edu - X - TikTok - Pinterest - Telegram - Instagram - Book a meeting - The Hillman Letter ## Press - The Tennessean - Yahoo Finance - EIN Presswire ## Sites - Hub - Expert witness - Giving - Advisory - Hillman Ventures - Public record A Dallas private family office for frontier biotech. Founded 1995. ### Firm ### More Nothing on this site is an offer to sell or a solicitation of an offer to buy any security. Nothing on this site is investment advice. Investigational status. Exosome, mesenchymal stem cell-derived extracellular vesicle, and Targeted Osmotic Lysis products referenced on this site are investigational and are not approved by the FDA for any indication. They are not available as a treatment. Last edited August 30, 2026. Expert witness: Dallas Healthcare Compliance Expert Witness Owner. Hillman Ventures, a Dallas, Texas private family office. Principal: Andrew Jonathan Hillman (Andrew J. Hillman). Andrew Hillman Dallas. Purpose. Describe the investment activity and convictions of Hillman Ventures, a Dallas private family office founded in 1995. What this site is not. This site is for general informational purposes only. It is not investment, financial, or tax advice, and nothing here is an offer, solicitation, or recommendation to buy or sell any security. It does not manage outside capital. Any securities offering is made only through definitive offering documents to eligible investors. Primary audience. Founders, co-investors, and operators in frontier biotech and FDA-regulated healthcare. Last updated:August 30, 2026. August 30, 2026, 1:20 PM CT Capital follows a clear regulatory pathway, defensible science, and an operating team that has shipped before. Position size scales with conviction and with the quality of the evidence. Risk is defined as permanent loss of capital and as regulatory or clinical failure, not as price volatility. The largest risk in healthcare is a misread of the FDA pathway. Investments are held across full development and commercialization cycles. The horizon is measured in years, not quarters. The office does not back wellness products without a regulatory pathway, unproven claims aimed at patients, businesses dependent on reimbursement arbitrage, or teams without operating experience in regulated medicine. - Hillman Ventures is a Dallas private family office founded in 1995. - It backs frontier biotech for inflammation, damaged tissue, and tumor-based cancers. - It invests its own capital and does not manage outside money. - Three convictions guide the work: regulatory pathway first, capital discipline as the durable advantage, and relationships that compound. - The principal, Andrew Hillman, operated FDA-regulated healthcare companies for three decades before investing, across hospitals, ambulatory surgical centers, pharmacies, CLIA- and COLA-accredited clinical laboratories, and FDA-registered implants and biologics. - Public-record filings related to past ventures are documented at andrewhillmanrecord.com. [source] This site is one component of a multi-domain ecosystem. Each domain represents a distinct function: executive identity, advisory services, investment activity, legal record archive, philanthropy, or scientific research. Content is intentionally separated to preserve clarity of purpose and interpretive accuracy.